Wire · regulatory
AdvaMed Encourages Risk-Based FDA Approach to Generative AI Medical Devices
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
AdvaMed has advocated for the FDA to use a risk-based approach leveraging existing regulatory frameworks for generative AI medical devices instead of creating new ones, aiming to support innovation while ensuring safety and effectiveness.
This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it between 19 Oct 2026 and 27 Oct 2026.
◆ ◆ The Wire takeaway
You face a regulatory environment pushing for updates to fit generative AI within existing medical device rules rather than new ones. Focus your product strategies around risk-based compliance to avoid delays and leverage FDA’s preference for evolving current controls.
◆ Coverage
5 sources · first reported 19 Oct 2026 · latest 27 Oct 2026
◆ Related on Wire
◆ Topics